Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents

British Journal of Cancer

Volumn 90, Issue 4, 2004, Pages 932-937

  Ireson, C R ^a   Chander, S K ^a   Purohit, A ^a   Perera, S ^a   Newman, S P ^a   Parish, D ^a   Leese, M P ^b   Smith, A C ^b   Potter, B V L ^b   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

2 methoxyoestradiol; 2 methoxyoestradiol bis sulphamate; Breast cancer; Pharmacokinetics; Sulphatase; Sulphatase inhibitor

Indexed keywords

2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL DISULFAMATE; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; UNCLASSIFIED DRUG; 2 METHOXYESTRIOL; 2-METHOXYESTRADIOL; 2-METHOXYESTRIOL; DRUG DERIVATIVE; ESTRIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MELANOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; SARCOMA; TUMOR XENOGRAFT; ANIMAL; ANIMAL DISEASE; BIOAVAILABILITY; BREAST TUMOR; DOSE RESPONSE; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SKIN TUMOR; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTRIOL; FEMALE; MELANOMA; MICE; MICE, NUDE; RATS; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 1642319678     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601591     Document Type: Article

References (30)

1. Ball P, Knuppen R (1980) Catecholoestrogens (2-and 4-hydroxyestrogens); chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol 232(Suppl): 1-127
2. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP (1998) 2-Hydroxyestrone; the 'good' estrogen. J Endocrinol 150: S259-S265
3. Bruggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Yusuf F, Burak WG (2001) 2-Methoxymethyestradiol: a new 2-methoxyoestrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 78: 145-156
4. Chander SK, Ireson CR, Fenton J, Newman SP, Leese MP, Potter BVL, Purohit A, Reed MJ (2003) Comparison of 2-methoxyestradiol and 2-methoxyestradiol-3, 17-bis-sulfamate in the Matrigel plug angiogenesis mouse model. Proc Am Assoc Cancer Res Abstr 44: 1156
5. D'Amato R, Lin CM, Flynn E, Folkman J, Hamel E (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerisation by interacting at the colchicine site. Proc Natl Acad Sci USA 91: 3964-3968
6. Dingli D, Timm M, Russell SJ, Witzing TE, Rajkumar SV (2002) Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 8: 3948-3954
7. Elger W, Palme H-J, Schwarz S (1998) Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Investig Drugs 7: 575-589
8. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B (1995) Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 55: 395-403
9. Ellison G, Klinowska T, Westwood PFR, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. J Clin Pathol Mol Pathol 55: 294-299
10. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxy-oestradiol inhibits angiogenesis and suppresses tumour growth. Nature (Lond) 368: 237-239
11. Hildago Aragones MI, Purohit A, Parish D, Sahm UG, Pouton CW, Potter BVL, Reed MJ (1996) Pharmacokinetics of oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 58: 611-617
12. Klauber N, Parangi S, Flynn E, D'Amato RJ (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86
13. Lakhani NJ, Sarkar MA, Venitz J, Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23: 165-172
14. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS (2002) 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of oestrogen receptors α and β. Cancer Res 62: 3691-3697
15. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS (2003) 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63: 468-475
16. Longcope C, Flood C, Femino A, Williams KIH (1980) Metabolism of 2-methoxyestrone in normal men. J Clin Endocrinol Metab 57: 277-282
17. Lottering M-L, Hang M, Seegers JC (1992) Effects of 17-β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52: 5926-5932
18. MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, Packham G (2000) Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 60: 5441-5450
19. Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51: 593-628
20. Merriam GR, MacLusky NJ, Picard MK, Naftolin F (1980) Comparative properties of the catechol estrogens. 1. Methylation by catechol-O- methyltransferase and binding to cytosol estrogen receptors. Steroids 36: 1-11
21. Newman SP, Leese MP, Purohit A, James DRC, Rennie CE, Potter BVL, Reed MJ (2004) Inhibition of in vitro angiogenesis by 2-methoxy and 2-ethyl estrogen sulfamates. Int J Cancer 109: 533-540
22. Purohit A, Vernon KA, Wagenaar Hummelinck AE, Woo LWL, Hejaz HAM, Potter BVL, Reed MJ (1998) The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 64: 269-275
23. Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ (1995) In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 63: 106-111
24. Raobaikady B, Purohit A, Chander SK, Woo LWL, Leese MP, Potter BVL, Reed MJ (2003) Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase by 2-methoxyestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 84: 351-358
25. Reed MJ, Purohit A, Woo LWL, Potter BVL (1996) The development of steroid sulphatase inhibitors. Endocr Relat Cancer 3: 9-23
26. Ruder HJ, Loriaux DL, Lispett MB (1972) Estrone sulfate: production rate and metabolism in man. J Clin Endocr Metab 51: 1020-1023
27. Seegers JC, Aveling M-L, Van Aswegen CH, Cross M, Koch F, Joubert WS (1989) The cytoxic effects of estradiol-17β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem Molec Biol 32: 797-809
28. Sledge GW, Miller KD, Hanye LG, Nguyen DD, Storniolo AM, Phillips E, Priblunda V, Gubish ER (2002) A phase I study of 2-methoxyestradiol in patients with refractory metastatic breast cancer. Proc Amer Soc Clin Oncol, abstract number 441
29. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Roa PN, Mooberry SL (2003) Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 63: 1538-1549
30. Zhu BT, Conney AH (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58: 2269-2277